Royalty Pharma (RPRX) vs Takeda Pharmaceutical (TAK)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Royalty Pharma (RPRX) has outperformed Takeda Pharmaceutical (TAK) over the past year, gaining 56.1% versus a gain of 33.0%. Over five years, RPRX leads with a +46.4% price change compared with +31.3% for TAK. Takeda Pharmaceutical is the larger company by market cap ($59.83 billion vs $32.90 billion), about 1.8 times the size.
On valuation, Royalty Pharma trades at a lower forward P/E (9.9x vs 35.3x for Takeda Pharmaceutical). Takeda Pharmaceutical offers the higher dividend yield (1067.81% vs 1.60%).
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | RPRX | TAK |
|---|---|---|
| Share price | $56.93 | $18.73 |
| Market cap | $32.90B | $59.83B |
| 1-day change | +1.28% | +1.13% |
| YTD return | +45.47% | +20.14% |
| 1-year return | +56.05% | +33.03% |
| 5-year return | +46.42% | +31.35% |
| P/E ratio (TTM) | 30.28 | — |
| Forward P/E | 9.93 | 35.34 |
| EPS (TTM) | $1.88 | $-0.34 |
| Dividend yield | 1.60% | 1067.81% |
| Annual dividend | $0.91 | $200.00 |
| Revenue (latest FY) | $2.38B | — |
| Revenue growth (YoY) | +5.06% | — |
| Net income (latest FY) | $770.95M | — |
| Operating margin | 65.58% | — |
| Net margin | 32.42% | — |
| 52-week high | $64.38 | $19.10 |
| 52-week low | $35.23 | $12.99 |
| Distance from 52-week high | -11.57% | -1.94% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +14.84% | +17.25% |
| Average volume | 2.92M | 3.04M |
| Shares outstanding | 445.28M | 3.19B |
| Employees | 100 | 47,029 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- RPRX has outperformed TAK by 23.0 percentage points over the past year.
- Takeda Pharmaceutical offers a meaningfully higher dividend yield (1067.81% vs 1.60%).
About Royalty Pharma
RPRX stock →Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovation in the biopharmaceutical industry in the United States. Its portfolio consists of royalties on approximately 35 marketed therapies and 20 development-stage product candidates that address various therapeutic areas, such as rare disease, oncology, neuroscience, infectious disease, hematology, and diabetes.
Health Care · Biotechnology: Pharmaceutical Preparations · 100 employees
About Takeda Pharmaceutical
TAK stock →Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma-derived therapies, oncology, vaccines, and neuroscience.
Health Care · Biotechnology: Pharmaceutical Preparations · 47,029 employees
RPRX vs TAK FAQ
Which is bigger, Royalty Pharma or Takeda Pharmaceutical?
Takeda Pharmaceutical (TAK) is larger, with a market capitalization of $59.83B compared with $32.90B for Royalty Pharma (RPRX).
Which stock has performed better over the past year, RPRX or TAK?
RPRX returned +56.05% over the past 12 months, compared with +33.03% for TAK (price return, excluding dividends). Past performance does not predict future results.
Which pays a higher dividend, Royalty Pharma or Takeda Pharmaceutical?
Takeda Pharmaceutical has the higher yield at 1067.81%, compared with 1.60% for Royalty Pharma.
Are Royalty Pharma and Takeda Pharmaceutical in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.